Tag: 053030

  • Binex Invests ₩55.7B: Expanding CDMO Capacity for Future Growth (Osong Plant Expansion)



    Binex Invests ₩55.7B: Expanding CDMO Capacity for Future Growth (Osong Plant Expansion) 대표 차트 이미지






    Binex’s ₩55.7B Investment – What’s Happening?

    On September 22, 2025, Binex announced a ₩55.7 billion investment (30.7% of its capital) to expand its Osong plant. The investment period is approximately 1 year and 2 months, from September 22, 2025, to November 30, 2026.

    Why This Investment?

    The core objective of this investment is to enhance Binex’s competitiveness in the biopharmaceutical CDMO business by expanding its production capacity. By expanding its global GMP-compliant production facilities, Binex aims to meet the growing demand for contract manufacturing from global pharmaceutical companies and improve cost competitiveness and profitability through economies of scale.

    So, What’s the Impact of Binex’s Investment?

    • Positive Impacts:
      • Enhanced CDMO business competitiveness and increased sales
      • Strengthened business portfolio and secured future growth drivers
      • Acceleration of the positive turnaround trend seen in the first half of 2025
    • Negative Impacts and Considerations:
      • Increased financial burden (potential increase in debt ratio)
      • Uncertainty regarding investment execution and commercial production timeline
      • Interest rate and exchange rate fluctuation risks

    What Should Investors Do?

    This investment is considered a positive event that enhances Binex’s mid-to-long-term growth potential. However, investors should continuously monitor the following:

    • Changes in financial soundness indicators
    • Timing of visible investment effects and actual performance
    • Changes in macroeconomic conditions such as interest rates and exchange rates


    FAQ

    What are the key details of Binex’s Osong plant expansion investment?

    Binex is investing ₩55.7 billion to expand its Osong plant. This aims to increase production capacity for its biopharmaceutical CDMO business and strengthen its global competitiveness.

    Will this investment have a positive impact on Binex?

    Yes, positive effects are expected, including increased production capacity, sales growth, and securing future growth drivers. However, there are also risks, such as increased financial burden and investment uncertainties.

    What should investors pay attention to?

    Investors should closely monitor Binex’s financial soundness, the timing of visible investment effects, and changes in macroeconomic conditions during the investment period.









    Binex Invests ₩55.7B: Expanding CDMO Capacity for Future Growth (Osong Plant Expansion) 관련 이미지
    Binex Invests ₩55.7B: Expanding CDMO Capacity for Future Growth (Osong Plant Expansion) 관련 이미지




  • Binex Secures KRW 20.8 Billion Biopharmaceutical Supply Contract: Investment Analysis and Buy Recommendation



    Binex Secures KRW 20.8 Billion Biopharmaceutical Supply Contract: Investment Analysis and Buy Recommendation 대표 차트 이미지






    Binex Signs KRW 20.8 Billion Biopharmaceutical Supply Contract

    Binex has entered into a commercial biopharmaceutical manufacturing and supply agreement with a global biopharmaceutical company, valued at KRW 20.8 billion. The contract period is from December 1, 2025, to June 30, 2027, a total of 1 year and 7 months. This represents a significant 16.01% of Binex’s recent annual revenue.

    Contract Significance and Growth Potential

    • Bio CDMO Business Expansion: This contract accelerates the growth of Binex’s bio CDMO business and enhances the visibility of future revenue growth, adding to the existing order backlog of KRW 121.1 billion.
    • Strengthened Global Partnership: Collaboration with a global biopharmaceutical company validates Binex’s technological capabilities and increases the potential for future contracts.
    • Increased Revenue and Profitability: The contract is expected to contribute to increased revenue and profitability, reflecting in financial results from the second half of 2025.

    Investment Risk Factors to Consider

    • Exchange Rate Volatility: Potential increase in raw material import costs.
    • Interest Rate Volatility: Possibility of increased interest burden due to higher debt ratio.
    • Production and Quality Control: Need to maintain high levels of production technology and quality control.
    • Intensifying Market Competition: Increased competition within the global CDMO market.

    Investment Strategy and Target Price

    Based on Binex’s positive growth outlook, we issue a “Buy” recommendation. The short-term target price is KRW 25,000 (3 months), and the fair target price is KRW 30,000 (12 months). Considering the growth potential of the bio CDMO business, the stable chemical pharmaceutical segment, and the positive market environment, the current stock price appears undervalued. However, investors should continuously monitor the risk factors mentioned above and adjust their investment strategies accordingly.



    Frequently Asked Questions (FAQ)

    What is the size of this contract?

    KRW 20.8 billion.

    Who is the counterparty to the contract?

    An undisclosed global biopharmaceutical company.

    What are Binex’s main businesses?

    Chemical pharmaceuticals and biopharmaceutical CDMO.

    What are the key considerations for investment?

    Investors should consider risk factors such as exchange rate and interest rate volatility, and intensifying market competition.









    Binex Secures KRW 20.8 Billion Biopharmaceutical Supply Contract: Investment Analysis and Buy Recommendation 관련 이미지
    Binex Secures KRW 20.8 Billion Biopharmaceutical Supply Contract: Investment Analysis and Buy Recommendation 관련 이미지